Calliditas Therapeutics AB (publ)

The company's financials show resilient growth, with revenue advancing from $24.98M in Q2 2023 to $559.78M in Q2 2024. Gross profit remained healthy with margins at 90% in Q2 2024 compared to 95% in Q2 2023. Operating income hit -$34.20M last quarter, sustaining a consistent -6% margin. Changes in R&D and SG&A spending did not hinder EBITDA, which stood at -$31.50M. Net income rose to -$47.48M, while earnings per share reached -$0.88. Strong cost management and operational efficiency kept profitability intact, underlining the company's stable and competitive market performance.